만성 B형 간염 및 HIV 환자의 HBsAg에 대한 경구 TLR8 작용제 Selgantolimod 연구
만성 B형 간염 및 HIV 환자의 HBsAg에 대한 경구용 TLR8 작용제 Selgantolimod의 안전성, 내약성 및 영향
The study aimed to assess safety and tolerability of oral toll-like receptor (TLR) 8 agonist Selgantolimod (SLGN) administered for 24 weeks in participants with both chronic hepatitis B (CHB) and HIV who had received suppressive antiviral therapy for both viruses for ≥5 years and have qHBsAg level >1000 (3 log10) IU/mL at screening. The study also evaluated if TLR8 stimulation with SLGN will reduce hepatitis B surface antigen (HBsAg) titers in the blood.
The primary hypotheses of this study were:
- Administration of the oral TLR8 agonist SLGN will be safe and well-tolerated in participants with both CHB and HIV on suppressive antiviral therapy for both viruses.
- TLR8 stimulation with SLGN will reduce HBsAg titers in the blood of participants with both CHB and HIV on suppressive antiviral therapy for both viruses.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
A5394 was a phase II, randomized, double-blind, placebo-controlled clinical trial to assess the safety, tolerability, and efficacy of 24 weeks of treatment with SLGN. Participants were randomized in a 3:1 ratio to receive SLGN or its placebo, and randomization was stratified by HBeAg status. Participants were planned to be on study for up to 48 weeks (24-week treatment phase and 24-week post-treatment follow-up). All participants were required to remain on their non-study-provided antiviral therapy throughout the study.
The primary efficacy analysis was planned to be conducted as a single-arm study of the SLGN study arm.
Accrual was terminated early and did not reach the target sample size of 48 due to ACTG Network funding disruptions.
연구 유형
연구 유형
등록 (실제)
등록
단계
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
California
-
San Diego, California, 미국, 92103
- UCSD Antiviral Research Center CRS (Site ID: 701)
-
-
Georgia
-
Atlanta, Georgia, 미국, 30308
- The Ponce de Leon Center CRS (Site ID: 5802)
-
-
New York
-
New York, New York, 미국, 10011
- Weill Cornell Chelsea CRS (Site ID: 7804)
-
-
North Carolina
-
Greensboro, North Carolina, 미국, 27401
- Greensboro CRS (Site ID: 3203)
-
-
Ohio
-
Cincinnati, Ohio, 미국, 45267-0405
- Cincinnati Clinical Research Site (Site ID: 2401)
-
Cleveland, Ohio, 미국, 44106
- Case CRS (Site ID: 2501)
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, 미국, 15213
- Univ of Pittsburgh (Site ID: 1001)
-
-
-
-
-
Rio de Janeiro, 브라질, 21040-360
- Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS (Site ID: 12101)
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, 브라질, 91350-180
- Instituto de Pesquisas em AIDS do Rio Grande do Sul - IPARGS CRS (Site ID: 12201)
-
-
-
-
-
Chiang Mai, 태국, 50200
- Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS (Site ID: 31784)
-
-
Bangkok
-
Pathum Wan, Bangkok, 태국, 10330
- Thai Red Cross AIDS Research Centre (TRC-ARC) CRS (Site ID: 31802)
-
-
-
-
-
Lima, 페루, 04
- Barranco CRS (Site ID: 11301)
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- HIV-1 infection
- Effective antiviral therapy for HIV (ART) and HBV that includes TDF, TAF, TDF/FTC, TDF/3TC (tenofovir disoproxil fumarate plus lamivudine), TAF/FTC, or entecavir (ETV), for ≥5 years immediately prior to study entry. ART is defined as including a minimum of two anti-HIV antivirals.
- CD4+ cell count ≥350 cells/mm3
- HIV-1 RNA <50 copies/mL measured on at least two occasions at least 12 weeks apart, with no documented value >200 copies/mL, over the 12 months prior to study entry.
- Positive or negative HBeAg
- Negative anti-HDV
- Current CHB infection
- HBV DNA level <50 IU/mL measured on at least two occasions at least 12 weeks apart, with no documented value ≥50 IU/mL, over the 12 months prior to study entry.
- Quantitative HBsAg >1000 IU/mL
- Hepatitis C virus (HCV) antibody negative, or if the participant is HCV antibody positive, an undetectable HCV RNA.
- Participants must agree to stay on an effective antiviral therapy for HIV (ART) and HBV throughout the study.
Exclusion Criteria:
- Receipt of treatment for HCV within 24 weeks prior to study entry
- Evidence of advanced fibrosis or cirrhosis (Metavir ≥F3 or equivalent).
- Current or prior history of clinical hepatic decompensation (e.g., ascites, encephalopathy, or variceal hemorrhage)
- History of HCC or cholangiocarcinoma
- Malignancy within 5 years prior to study entry. NOTE: A history of non-melanoma skin cancer (e.g., basal cell carcinoma or squamous cell skin cancer) is not exclusionary.
- History of solid organ transplantation
- Presence of any active or acute AIDS-defining opportunistic infections within 60 days prior to study entry
- History of uveitis or posterior synechiae
- Breastfeeding
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 삼루타
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Arm A
Participants received Selgantolimod 3 mg (two 1.5 mg tablets) once weekly for 24 weeks. |
Two 1.5 mg tablets taken orally once a week
다른 이름들:
|
|
위약 비교기: Arm B
Participants received matching Placebo for Selgantolimod once weekly for 24 weeks. |
Two matching placebo tablets taken orally once a week |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Proportion of Participants Who Experienced Grade ≥2 Adverse Events (AEs) in Arm A
기간: From study treatment initiation through Week 24
|
An adverse event (AE) is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or diagnosis that occurs in a study participant during the conduct of the study REGARDLESS of the attribution. This includes any occurrence that is new in onset or aggravated in severity or frequency from the baseline condition. All AEs that are reported must have their severity graded. Adverse events were graded according to the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), corrected Version 2.1, July 2017. Adverse events were graded on a scale from 1-5: 1=mild, 2=moderate, 3=severe, 4=life-threatening, 5=death. Higher scores/grades mean a worse outcome. The proportion of participants with Grade 2 or higher adverse events was calculated, along with a two-sided 95% confidence interval constructed using the Clopper-Pearson exact method for binomial data. |
From study treatment initiation through Week 24
|
|
Proportion of Participants Who Prematurely Discontinued Treatment Due to Adverse Events (AEs) in Arm A
기간: From study treatment initiation through Week 24
|
The proportion of participants who had premature discontinuation of Selgantolimod due to adverse event(s) was calculated, along with a two-sided 95% confidence interval constructed using the Clopper-Pearson exact method for binomial data. |
From study treatment initiation through Week 24
|
|
Proportion of Participants With ≥1 log10 IU/mL Decline From Baseline in Quantitative HBsAg (qHBsAg) After SLGN Treatment at Week 24
기간: Week 24
|
The proportion of participants who experienced ≥1 log10 IU/mL decline in quantitative HBsAg at Week 24 was calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data. |
Week 24
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Proportion of Participants With ≥1 log10 IU/mL Decline From Baseline in qHBsAg at Any Time During the Study After SLGN Treatment Initiation
기간: From Baseline (Entry) through Week 48
|
The proportion of participants who experienced ≥1 log10 IU/mL decline in quantitative HBsAg at any time during the study after SLGN treatment initiation will be calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data. |
From Baseline (Entry) through Week 48
|
|
Proportion of Participants With ≥0.5 log10 IU/mL Decline From Baseline in qHBsAg After SLGN Treatment at Week 24
기간: Week 24
|
The proportion of participants who experienced ≥0.5 log10 IU/mL decline in quantitative HBsAg at Week 24 was calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data. |
Week 24
|
|
Proportion of Participants With ≥0.5 log10 IU/mL Decline in qHBsAg From Baseline at Any Time During the Study After SLGN Treatment Initiation
기간: From Baseline (Entry) through Week 48
|
The proportion of participants who experienced ≥0.5 log10 IU/mL decline in quantitative HBsAg at any time during the study after SLGN treatment initiation will be calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data. |
From Baseline (Entry) through Week 48
|
|
Proportion of Participants Who Achieve HBsAg Loss After SLGN Initiation and Who Sustain HBsAg Loss During Follow-up
기간: From Baseline (Entry) through Week 48
|
Sustained HBsAg loss is defined as HBsAg converting from positive to negative after initiation of SLGN, without any subsequent positive HBsAg result. The proportion of participants who achieved HBsAg loss after SLGN initiation and who sustained HBsAg loss during follow-up will be calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data. |
From Baseline (Entry) through Week 48
|
|
Changes From Baseline in qHBsAg Levels
기간: Baseline (Entry) and Weeks 4, 12, 24, 36 and 48
|
The absolute change in qHBsAg level refers to the value at the follow-up time point minus the value at Baseline (Entry). |
Baseline (Entry) and Weeks 4, 12, 24, 36 and 48
|
|
Proportion of Hepatitis B E-antigen (HBeAg) Positive Participants at Baseline Who Lose HBeAg at Any Time During the Study
기간: From Baseline (Entry) through Week 48
|
HBeAg loss is defined as HBeAg changing from positive to negative. The proportion of participants who lose HBeAg at any time during the study will be calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data. |
From Baseline (Entry) through Week 48
|
|
Proportion of Hepatitis B E-antibody (Anti-HBe) Negative Participants at Baseline Who Develop Anti-HBe at Any Time During the Study
기간: From Baseline (Entry) through Week 48
|
Developing anti-HBe, or anti-HBe gain, is defined as HBeAb changing from negative to positive. The proportion of participants who develop HBeAb at any time during the study will be calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data. |
From Baseline (Entry) through Week 48
|
|
Proportion of Hepatitis B Surface Antibody (Anti-HBs) Negative Participants at Baseline Who Develop Anti-HBs at Any Time During the Study
기간: From Baseline (Entry) through Week 48
|
Developing anti-HBs, or anti-HBs gain, is defined as HBsAb changing from negative to positive. The proportion of participants who develop HBsAb at any time during the study will be calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data. |
From Baseline (Entry) through Week 48
|
|
Number of Participants With Plasma HIV RNA >50 Copies/mL
기간: Weeks 2, 4, 24 and 48
|
The number of participants with detectable plasma HIV RNA >50 copies/mL will be reported. |
Weeks 2, 4, 24 and 48
|
|
Number of Participants With Serum HBV DNA >50 IU/mL
기간: Weeks 2, 4, 24 and 48
|
The number of participants with detectable serum HBV DNA >50 copies/mL will be reported. |
Weeks 2, 4, 24 and 48
|
공동 작업자 및 조사자
스폰서
스폰서
협력자
협력자
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (실제)
기본 완료
연구 완료 (실제)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- A5394
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Individual participant data that underlie results in the publication, after deidentification
IPD 공유 기간
Beginning 3 months following publication and available throughout period of funding of the Advancing Clinical Therapeutics Globally (ACTG) by NIH
IPD 공유 액세스 기준
With whom? Researchers who provide a methodologically sound proposal for use of the data that is approved by the ACTG.
For what types of analyses? To achieve aims in the proposal approved by the ACTG.
By what mechanism will data be made available? Researchers may submit a request for access to data using the ACTG "Data Request" form at: https://actgnetwork.org/submit-a-proposal/. Researchers of approved proposals will need to sign an ACTG Data Use Agreement before receiving the data.
IPD 공유 지원 정보 유형
- 연구_프로토콜
- 수액
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .